المؤلفون: Zhu X; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Medicine, University of California San Francisco, San Francisco, CA, United States., Chan E; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Pathology, Stanford Medical Center, Stanford, CA, United States., Turski ML; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States., Mendez CE; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States., Hsu SC; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Medicine, University of California San Francisco, San Francisco, CA, United States., Kumar V; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Medicine, University of California San Francisco, San Francisco, CA, United States., Shipp C; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Medicine, University of California San Francisco, San Francisco, CA, United States., Jindal T; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Medicine, University of California San Francisco, San Francisco, CA, United States., Chang K; School of Medicine, University of California San Francisco, San Francisco, CA, United States., Onodera C; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States., Devine WP; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Pathology, University of California San Francisco, San Francisco, CA, United States., Grenert JP; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Pathology, University of California San Francisco, San Francisco, CA, United States., Stohr BA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Pathology, University of California San Francisco, San Francisco, CA, United States., Ding CC; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Pathology, University of California San Francisco, San Francisco, CA, United States., Stachler MD; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Pathology, University of California San Francisco, San Francisco, CA, United States., Quigley DA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Urology, University of California San Francisco, San Francisco, CA, United States., Feng FY; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, United States., Chu CE; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Urology, University of California San Francisco, San Francisco, CA, United States., Porten SP; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Urology, University of California San Francisco, San Francisco, CA, United States., Chou J; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Medicine, University of California San Francisco, San Francisco, CA, United States., Friedlander TW; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Medicine, University of California San Francisco, San Francisco, CA, United States., Koshkin VS; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.; Department of Medicine, University of California San Francisco, San Francisco, CA, United States.

المصدر: The oncologist [Oncologist] 2024 Jun 22. Date of Electronic Publication: 2024 Jun 22.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

المؤلفون: Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., O'Donnell PH; University of Chicago, Chicago, IL., Hoimes CJ; Duke Cancer Institute, Duke University, Durham, NC., Petrylak DP; Yale Cancer Center, New Haven, CT., Flaig TW; University of Colorado Comprehensive Cancer Center, Aurora, CO., Moon HH; Kaiser Permanente Southern California, Riverside, CA., Friedlander TW; University of California San Francisco Medical Center, San Francisco, CA., Mar N; University of California Irvine, Irvine, CA., McKay RR; University of California San Diego, San Diego, CA., Srinivas S; Stanford University Medical Center, Stanford, CA., Gravis G; Institut Paoli-Calmettes, Marseille, France., Ramamurthy C; MD Anderson Cancer Center, University of Texas Health, San Antonio, TX., Bupathi M; Rocky Mountain Cancer Centers, Littleton, CO., Bracarda S; Azienda Ospedaliera Santa Maria Terni, Terni, Italy., Wright P; Seagen Inc, Bothell, WA., Hepp Z; Seagen Inc, Bothell, WA., Carret AS; Seagen Inc, Bothell, WA., Yu Y; Seagen Inc, Bothell, WA., Dillon R; Astellas Pharma Inc, Northbrook, IL., Kataria R; Merck & Co, Inc, Rahway, NJ., Beaumont JL; Clinical Outcomes Solutions Ltd, Tucson, AZ., Purnajo I; Clinical Outcomes Solutions Ltd, Tucson, AZ., Rosenberg JE; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 20; Vol. 42 (12), pp. 1403-1414. Date of Electronic Publication: 2024 Jan 12.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal* , Antibodies, Monoclonal, Humanized* , Carcinoma, Transitional Cell* , Sleep Initiation and Maintenance Disorders*, Humans ; Cisplatin ; Pain ; Patient Reported Outcome Measures ; Quality of Life/psychology

المؤلفون: Chang H; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Marquez J; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Chen BK; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Kim DM; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Cheng ML; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Liu EV; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Yang H; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California., Zhang L; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California., Sinha M; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Cheung A; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Kwek SS; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Chow ED; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Department of Biochemistry and Biophysics, Center for Advanced Technologies, University of California San Francisco, San Francisco, California., Bridge M; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California., Aggarwal RR; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California., Friedlander TW; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Small EJ; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California., Anderson M; Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, California., Fong L; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

المصدر: Cancer immunology research [Cancer Immunol Res] 2024 Apr 02; Vol. 12 (4), pp. 453-461.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE

مواضيع طبية MeSH: Bone Neoplasms*/drug therapy , Bone Neoplasms*/prevention & control , Bone Neoplasms*/secondary , Denosumab*/therapeutic use, Humans ; Male ; Kidney Neoplasms/drug therapy ; RANK Ligand/antagonists & inhibitors ; Prostatic Neoplasms/drug therapy

المؤلفون: Shipp C; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Jindal T; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Chou J; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Friedlander TW; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Koshkin VS; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address: Vadim.Koshkin@ucsf.edu., Kumar V; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address: Vipul.Kumar@ucsf.edu.

المصدر: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Apr; Vol. 22 (2), pp. 315-321. Date of Electronic Publication: 2023 Nov 25.

نوع المنشور: Case Reports

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Transitional Cell*/drug therapy , Urinary Bladder Neoplasms*/drug therapy, Humans ; Antibodies, Monoclonal/therapeutic use

المؤلفون: Hoimes CJ; Duke Cancer Institute; Duke University, Durham, NC, USA., Flaig TW; University of Colorado Comprehensive Cancer Center, Aurora, CO, USA., Milowsky MI; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Friedlander TW; University of California San Francisco Medical Center, San Francisco, CA, USA., Bilen MA; Winship Cancer Institute of Emory University, Hematology & Medical Oncology, Atlanta, GA, USA., Gupta S; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Srinivas S; Stanford University Medical Center, Stanford, CA, USA., Merchan JR; University of Miami, Medical Oncology, Miami, FL, USA., McKay RR; University of California San Diego Moores Cancer Center, San Diego, CA, USA., Petrylak DP; Yale Comprehensive Cancer Center, New Haven, CT, USA., Sasse C; Astellas Pharma Global Development, Northbrook, IL, USA., Moreno BH; Merck & Co., Inc., Rahway, NJ, USA., Yu Y; Seagen Inc., Bothell, WA, USA., Carret AS; Seagen Inc., Bothell, WA, USA., Rosenberg JE; Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, NY, USA.

المصدر: Future oncology (London, England) [Future Oncol] 2024 Mar; Vol. 20 (7), pp. 351-360. Date of Electronic Publication: 2023 Nov 23.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Urologic Neoplasms*/drug therapy , Urologic Neoplasms*/pathology , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/pathology , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology, Humans ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal/adverse effects

المؤلفون: O'Donnell PH; University of Chicago, Chicago, IL., Milowsky MI; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Petrylak DP; Yale Cancer Center, New Haven, CT., Hoimes CJ; Duke Cancer Institute, Duke University, Durham, NC., Flaig TW; University of Colorado Comprehensive Cancer Center, Aurora, CO., Mar N; University of California at Irvine, Irvine, CA., Moon HH; Kaiser Permanente Southern California, Riverside, CA., Friedlander TW; University of California at San Francisco, San Francisco, CA., McKay RR; University of California at San Diego, San Diego, CA., Bilen MA; Emory University Winship Cancer Institute, Atlanta, GA., Srinivas S; Stanford Cancer Center, Stanford, CA., Burgess EF; Levine Cancer Center, Charlotte, NC., Ramamurthy C; University of Texas Health Sciences Center at San Antonio, San Antonio, TX., George S; Roswell Park Cancer Center, Buffalo, NY., Geynisman DM; Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA., Bracarda S; Azienda Ospedaliera Santa Maria di Terni, Terni, Italy., Borchiellini D; Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France., Geoffrois L; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France., Maroto Rey JP; Hospital de la Santa Creu i Sant Paul, Barcelona, Spain., Ferrario C; Jewish General Hospital, Montreal, Quebec, Canada., Carret AS; Seagen Inc, Bothell, WA., Yu Y; Seagen Inc, Bothell, WA., Guseva M; Astellas Pharma, Northbrook, IL., Homet Moreno B; Merck & Co Inc, Rahway, NJ., Rosenberg JE; Memorial Sloan Kettering Cancer Center, New York, NY.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Sep 01; Vol. 41 (25), pp. 4107-4117. Date of Electronic Publication: 2023 Jun 27.

نوع المنشور: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Cisplatin*/adverse effects , Carcinoma, Transitional Cell*, Humans ; Antibodies, Monoclonal, Humanized/therapeutic use

المؤلفون: Kwon DH; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. Electronic address: daniel.kwon@ucsf.edu., Shakhnazaryan N; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Shui D; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Hong JC; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; Department of Radiation Oncology, University of California, San Francisco, CA; Bakar Computational Health Sciences Institute, University of California, San Francisco, CA., Mohamad O; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; Department of Radiation Oncology, University of California, San Francisco, CA; Department of Urology, University of California, San Francisco, CA., de Kouchkovsky I; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Borno HT; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Bose R; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Chou J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Desai A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Fong L; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Friedlander TW; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Koshkin VS; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Aggarwal RR; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Feng FY; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; Department of Radiation Oncology, University of California, San Francisco, CA., Hope TA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA., Small EJ; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.

المصدر: Urologic oncology [Urol Oncol] 2023 Mar; Vol. 41 (3), pp. 145.e7-145.e15. Date of Electronic Publication: 2022 Nov 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Radiosurgery*, Male ; Humans ; Prostate-Specific Antigen ; Gallium Radioisotopes ; Treatment Outcome ; Androgen Antagonists ; Retrospective Studies ; Prospective Studies

المؤلفون: Hoimes CJ; Duke Cancer Institute, Duke University, Durham, NC.; Seidman Cancer Center at University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH., Flaig TW; University of Colorado Comprehensive Cancer Center, Aurora, CO., Milowsky MI; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Friedlander TW; University of California San Francisco Medical Center, San Francisco, CA., Bilen MA; Winship Cancer Institute of Emory University, Atlanta, GA., Gupta S; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH., Srinivas S; Stanford University Medical Center, Stanford, CA., Merchan JR; University of Miami, Miami, FL., McKay RR; University of California San Diego, San Diego, CA., Petrylak DP; Yale Cancer Center, New Haven, CT., Sasse C; Astellas, Northbrook, IL., Moreno BH; Merck & Co, Inc, Kenilworth, NJ., Yu Y; Seagen Inc, Bothell, WA., Carret AS; Seagen Inc, Bothell, WA., Rosenberg JE; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 01; Vol. 41 (1), pp. 22-31. Date of Electronic Publication: 2022 Aug 30.

نوع المنشور: Multicenter Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Cisplatin*/adverse effects , Neoplasms*/drug therapy, Humans ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Chou J; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: Jonathan.Chou@ucsf.edu., Trepka K; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Radiation Oncology, University of California, San Francisco, CA, USA; Medical Scientist Training Program, University of California, San Francisco, CA, USA., Sjöström M; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Radiation Oncology, University of California, San Francisco, CA, USA., Egusa EA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Radiation Oncology, University of California, San Francisco, CA, USA., Chu CE; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, CA, USA., Zhu J; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Radiation Oncology, University of California, San Francisco, CA, USA., Chan E; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Pathology, University of California, San Francisco, CA, USA., Gibb EA; Decipher Biosciences, Inc., San Diego, CA, USA., Badura ML; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Radiation Oncology, University of California, San Francisco, CA, USA., Contreras-Sanz A; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Stohr BA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Pathology, University of California, San Francisco, CA, USA., Meng MV; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, CA, USA., Pruthi RS; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, CA, USA., Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Black PC; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Porten SP; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, CA, USA., Koshkin VS; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Friedlander TW; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Feng FY; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Radiation Oncology, University of California, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, CA, USA. Electronic address: Felix.Feng@ucsf.edu.

المصدر: European urology oncology [Eur Urol Oncol] 2022 Dec; Vol. 5 (6), pp. 714-718. Date of Electronic Publication: 2022 Feb 23.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/genetics , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/genetics , Urinary Bladder Neoplasms*/pathology , Immunoconjugates*/therapeutic use, Humans ; Cell Adhesion Molecules/genetics ; Cell Adhesion Molecules/metabolism ; Cell Adhesion Molecules/therapeutic use ; RNA, Messenger/therapeutic use

المؤلفون: Friedlander TW; Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

المصدر: Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2022 Aug; Vol. 20 (8), pp. 487-489.

نوع المنشور: Interview

بيانات الدورية: Publisher: Millennium Medical Pub Country of Publication: United States NLM ID: 101167661 Publication Model: Print Cited Medium: Internet ISSN: 1543-0790 (Print) Linking ISSN: 15430790 NLM ISO Abbreviation: Clin Adv Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/diagnosis , Prostatic Neoplasms*/pathology, Humans ; Male